Volanesorsen to Prevent Acute Pancreatitis in Hypertriglyceridemia
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The trial findings are consistent with a meta-analysis of three randomized, placebo-controlled trials of volanesorsen, which showed an association between treatment and a reduction in the incidence of acute pancreatitis.
“Our findings are consistent with the results of a meta-analysis of three randomized, placebocontrolled trials of volanesorsen, which showed an association between treatment and a reduction in the incidence of acute pancreatitis. 35”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [35]
Cites
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187 · see citing works
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1715944 · Cited by 669 · see citing works
Self-citationGouni-Berthold, I., Alexander, V. J., Yang, Q., Hurh, E., Steinhagen-Thiessen, E., Moriarty, P. M., Hughes, S. G., Gaudet, D., Hegele, R. A., O'Dea, L. S. L., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00046-2 · Cited by 232 · see citing works
Self-citationOral, E. A., Garg, A., Tami, J. A., Huang, E. A., O'Dea, L. S. L., Schmidt, H., Tiulpakov, A. N., Mertens, A. C., Alexander, V. J., Watts, L. M., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.008 · Cited by 75 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf190 · Cited by 688 · see citing works
Self-citationOlezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
Stroes, E. S. G., Alexander, V. J., Karwatowska-Prokopczuk, E., Hegele, R. A., Arca, M., Ballantyne, C. M., Soran, H., Prohaska, T. A., Xia, S., Ginsberg, H. N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400201 · Cited by 271 · see citing works
Self-citationOlezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402309 · Cited by 198 · see citing works
Self-citationPlozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Gaudet, D., Pall, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. M. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.0959 · Cited by 172 · see citing works
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120479 · Cited by 180 · see citing works
Párniczky, A., Mikó, A., Uç, A., Singh, A. N., Elhence, A., Saluja, A., Masamune, A., Dayyeh, B. K. A., Davidson, B. R., Wilcox, C. M., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.04.020 · Cited by 159 · see citing works
Patel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L., Bird, M. D., Coles, S., Marrs, J., Peng, C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 68 · see citing works
Spagnuolo, C. M., Wang, J., McIntyre, A. D., Kennedy, B. A., & Hegele, R. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae613 · Cited by 38 · see citing works
Self-citationAdvances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 30 · see citing works
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32 · see citing works
Self-citationNew approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26 · see citing works
Wang, L., Gao, Z., Tian, M., Liu, L., Xie, J., Chen, M., Huang, Z., Dong, B., Li, W., Shi, L., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c01495 · Cited by 24 · see citing works
Residual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 24 · see citing works
Self-citationSyed‐Abdul, M. M., Tian, L., Hegele, R. A., & Lewis, G. F. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00028-2 · Cited by 21 · see citing works
Self-citationFamilial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 20 · see citing works
Self-citationEtiology and emerging treatments for familial chylomicronemia syndrome
Spagnuolo, C. M., & Hegele, R. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365787 · Cited by 17 · see citing works
Self-citationOlezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 15 · see citing works
de Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 15 · see citing works
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16 · see citing works
Self-citationMaidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 11 · see citing works
Self-citationMRG15 promotes cell apoptosis through inhibition of mitophagy in hyperlipidemic acute pancreatitis
Gu, B., Yu, W., Huang, Z., Bai, J., Liu, S., Ren, B., Wang, P., Sun, L., Wen, J., Yang, Z., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02034-4 · Cited by 9 · see citing works
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 11 · see citing works
D’Erasmo, L., Tramontano, D., Di Costanzo, A., Casula, M., Galimberti, F., Baratta, F., Cefalù, A. B., Tarugi, P. M., Calandra, S., Zambon, A., et al. (2025) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.125.323340 · Cited by 9 · see citing works
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 45 · see citing works
Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review
Subramanian, S., Soran, H., Kessler, A. S., McClain, M. R., Eckel, R. H., & Rosenson, R. S. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106648 · Cited by 9 · see citing works
Approach to the Adult Patient with Chylomicronemia
Hegele, R. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf701 · Cited by 9 · see citing works
Self-citationMiller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7 · see citing works
Brown, A. S., Moulin, P., Dibble, A., Alexander, V. J., Li, L., Gaudet, D., Witztum, J. L., Tsimikas, S., & Hegele, R. A. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.008 · Cited by 6 · see citing works
Self-citationToth, P. P., & Banach, M. (2025) · Archives of Medical Science · doi:10.5114/aoms/216960 · Cited by 6 · see citing works
Li, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 8 · see citing works
Weijs, B. M., Oostveen, R. F., Kraaijenhof, J. M., & Stroes, E. S. G. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000906 · Cited by 5 · see citing works
Self-citationPawelec, N., Durko, Ł., & Małecka-Wojciesko, E. (2025) · Cancers · doi:10.3390/cancers17111891 · Cited by 5 · see citing works
Tan, P., Lu, S., Chen, Q., Ma, H., Kong, W., Huang, X., Yu, C., & Jin, M. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02511-y · Cited by 5 · see citing works
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 4 · see citing works
Self-citationLoomba, R. S., de‐Madaria, E., Afghani, E., Singh, V. K., & Leeper, N. J. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70623 · Cited by 4 · see citing works
Lipoprotein apheresis in the era of new lipid-lowering therapies
Sbrana, F., Pino, B. D., Schettler, V. J. J., Muso, E., Harada-Shiba, M., Mola, M. D., Kagitani, M., Pineda, E., Selke, N., Jenke, S., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag328 · Cited by 4 · see citing works
den Hollander, B., Brands, M. M. M. G., Nijhuis, I. J. M., van Troostwijk, L. J. A. E. D., van Essen, P., Hofsteenge, G. H., Koot, B. G. P., Müller, A. R., Tseng, L. A., Stroes, E. S. G., et al. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108347 · Cited by 4 · see citing works
Self-citationTang, X. L., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414126 · Cited by 4 · see citing works
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Watts, G. F., Hegele, R. A., & Leeper, N. J. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2412616 · Cited by 4 · see citing works
Self-citationZhang, X., Wang, Y., Miao, X., Guan, R., & Li, H. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174719 · Cited by 3 · see citing works
Heath, O., Allender, B., Smith, J. D., Savva, E., Spencer, L., Bannister, E. G., Brown, N. J., Evans, M. S., Kiss, S., Rozen, T. H., et al. (2024) · JIMD Reports · doi:10.1002/jmd2.12434 · Cited by 3 · see citing works
Ogunniyi, K. E., Aghasili, C. C., Akinmoju, O. D., Olaiya, V. O., Abib, O. M., Odueke, A., Popoola, H. A., Onyenokwe, V., Onaolapo, D., Usman, A.-A. M., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00762-9 · Cited by 3 · see citing works
Reducing the Risk of Pancreatitis by Inhibiting APOC3
Stitziel, N. O. (2025) · New England Journal of Medicine · doi:10.1056/nejme2411605 · Cited by 3 · see citing works
Idiopathic recurrent acute pancreatitis: current and future approaches to management
Singh, P. K., Mahapatra, S. J., & Garg, P. K. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001122 · Cited by 2 · see citing works
Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent
Marston, N., & Zimerman, A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001013 · Cited by 2 · see citing works
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 2 · see citing works
Kessler, A. S., Vera‐Llonch, M., Karwatowska‐Prokopczuk, E., Alexander, V. J., Ann, Q., Herrera, C. M., Paparrodopoulos, S., Xia, S., Stroes, E. S. G., Baum, S. J., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.018 · Cited by 2 · see citing works
Self-citationKatzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2 · see citing works
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 2 · see citing works
Self-citationReal life evidence of volanesorsen for familial chylomicronemia syndrome in Colombia
Román-Gonzaléz, A., Castellanos, A., Perdomo, D. F. S., Peña, C. A. C., Vargas, J. J., Mendivil, C. O., & Gutiérrez-Restrepo, J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.203 · Cited by 2 · see citing works
Bajaj, A., Oral, E. A., Brown, A. S., Gaudet, D., Alexander, V. J., Karwatowska‐Prokopczuk, E., & Baum, S. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101352 · Cited by 2 · see citing works
Self-citationYoo, J. H. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e19 · Cited by 1 · see citing works
ESC-Leitlinien-Update 2025 zur Dyslipidämie
Hohneck, A. L., & Weingärtner, O. (2025) · Herz · doi:10.1007/s00059-025-05354-6 · Cited by 1 · see citing works
Meghashree, N., B, K. C., & Shivaraj, D. R. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.72 · Cited by 1 · see citing works
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 1 · see citing works
Self-citationRemnant cholesterol — The transition from biomarker to risk factor
Rosenson, R. S., Velamuri, D. N., Muntner, P., & Goonewardena, S. N. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120755 · Cited by 2 · see citing works
Guay, S., Gagnon, É., Paquette, M., Thériault, S., Arsenault, B. J., & Baass, A. W. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16759 · Cited by 1 · see citing works
Plozasiran and Apolipoprotein C-III Inhibition
Schwartz, G. G., & Cobbaert, C. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.519 · Cited by 1 · see citing works
Thomas, J. A. (2024) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20240556
Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia
Galiuto, L., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae351
Einsatz von Olezarsen bei Hypertriglyzeridämie und familiärem Chylomikronämiesyndrom
Leitolf, H., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01785-1
Moury, J., Nendumba, G., Robert, A., Hauqiert, B., Vornicu, O., Blackman, S., Perriens, E., Bendoumou, M., Sánchez, A., Buttice, E., et al. (2024) · Annals of Translational Medicine · doi:10.21037/atm-24-63
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437524
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.004 · Cited by 1 · see citing works
New drugs for treating dyslipidemias. From small molecules to small interfering RNAs
Masana, L., & Ibarretxe, D. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100739
Gong, Z., Xia, Y., Sun, C., Zheng, W., Du, T., Liang, L., Wang, R., Zhang, K., Yang, Y., Sun, M., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.07.010
Pancreatitis aguda secundaria a hipertrigliceridemia: reporte de caso
Pineda., M. A. A., Castrillon, J. D. C., González, M., Tamayo, S. H. G., & Alvarez, I. (2025) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.1188
Alexander, V. J., Prohaska, T. A., Karwatowska‐Prokopczuk, E., Xia, S., & Tsimikas, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.007
Self-citationSbrana, F., Pino, B. D., Corciulo, C., Bigazzi, F., & Sampietro, T. (2025) · Endocrine · doi:10.1007/s12020-025-04334-4
Liu, T., Peng, L., Huo, Y., Lu, T., & Lv, X. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s542198
Fan, C., Hong-ji, W., Guo, M., Pan, Y., Qin, Z., Dai, Z., Kong, H. H. Y., Huang, F., Lin, Y., & Zhang, J. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.139716
Yao, L., Yang, X., Sutton, R., Xia, Q., & Huang, W. (2025) · MedComm · doi:10.1002/mco2.70554
Feroz, K., Parvez, A., Ramzan, N. U. H., Asghar, T., Cheema, A. H., Malik, A. P., Fatima, T., Iqbal, J., & Sathian, B. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/9984822
Correlation between acute pancreatitis and total psoas area
Liu, X., Zhang, Y., Yang, G., Lin, Z., Liu, Y., lin, Y., Lu, Y., Lai, M., & Yan, G. (2026) · Technology and Health Care · doi:10.1177/09287329251410739
Le syndrome d’hyperchylomicronémie familiale (SHF)
Langlois, C., & Charrière, S. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.01.003
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2 · see citing works
Harangi, M., Nádró, B., Diószegi, Á., & Paragh, G. (2026) · Magyar Belorvosi Archívum · doi:10.59063/mba.2026.79.1.2
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
Self-citationMourre, F., & Béliard, S. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.05.002
Wang, L., He, M., Xie, H., Mao, W., Liu, Y., Ke, L., 邹鑫森, & Li, W. (2026) · European journal of medical research · doi:10.1186/s40001-026-04732-y
Österreichischer Lipidkonsensus 2026
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Labenz, J., & Madisch, A. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2869-1150
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Tsimikas, S., Morgan, E. S., Sharma, J., Lin, T., Mullick, A. E., Prakash, T. P., Swayze, E. E., & Prohaska, T. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.012
Self-citationZimerman, A., & Marston, N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01472-6
- Authors
- Alexander, V. J., Karwatowska-Prokopczuk, E., Prohaska, T. A., Li, L., Geary, R. S., Gouni-Berthold, I., Oral, E. A., Hegele, R. A., Stroes, E. S. G., Witztum, J. L., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- Ionis Pharmaceuticals, Carlsbad, CA
- University of Cologne, Cologne, Germany
- University of Michigan (US)
- Western University (CA)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02
- Volume
- 390
- Issue
- 5
- Pages
- 476-477
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391378948
- Cited by
- 85
- References
- 4
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 23
- FWCI
- 35.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- volanesorsen, acute pancreatitis, hypertriglyceridemia, triglyceride-lowering therapy, apolipoprotein C-III, triglyceride-rich lipoproteins
- MeSH terms
- Acute Disease, Humans, Hyperlipidemias, Oligonucleotides, Pancreatitis, Triglycerides, Hypertriglyceridemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
